BioSpace News Archive

Wilmington, Delaware, United States, Transparency Market Research Inc.: Medical imaging has made tremendous strides on the back two pillars: continuous technological advancements and the sheer pace of digital transformation in radiology.

Quoin Pharmaceuticals Inc. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, has entered into the License and Distribution Agreement and the Supply Agreement with Endo Ventures Limited, a subsidiary of Endo International plc (NASDAQ:ENDP), for the development, registration, supply, commercialization and distribution of QRX003.

Subtle Medical, a healthcare technology company improving the quality and efficiency of medical imaging, announced they are expanding their partnership with Incepto.

Viveon Health Acquisition Corp. announced that VHAQ filed a registration statement on Form S-4 (the “Registration Statement”) with the U.S. Securities and Exchange Commission (“SEC”) on July 13, 2022.

ImpediMed Limited (ASX: IPD) is pleased to announce that two abstracts evaluating use of ImpediMed’s SOZO® Digital Health Platform in heart failure patients were accepted for poster presentation at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022 taking place from September 30 to October 3 in Washington D.C.

Alzheimer disease is a neurodegenerative disorder which is characterized by significant cognitive deficits, behavioral changes, sleep disorders, and loss of functional autonomy.

Parkinson’s disease is a most commonly diagnosed age related neurodegenerative disorder, which affects the normal movements of body due to genetic and environmental factors.

Today, the Honourable Jean-Yves Duclos, Minister of Health, and the Honourable Filomena Tassi, Minister of Public Services and Procurement, announced that the Government of Canada has signed a new contract with GlaxoSmithKline (GSK) to support sustained influenza pandemic readiness.

Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced that the European Commission (EC) has granted conditional marketing authorization for Kinpeygo® for the treatment of primary immunoglobulin A (IgA) nephropathy (IgAN) in adults at risk of rapid disease progression with a urine protein-to-creatinine ratio (UPCR) ≥1.5 g/gram.

Bavarian Nordic A/S (OMX: BAVA) announced today that the U.S. Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, has ordered an additional 2.5 million doses of liquid-frozen JYNNEOS®.